$402 Million is the total value of Eversept Partners, LP's 61 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 82.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZGNX | Buy | ZOGENIX INC | $49,793,039 | +92.7% | 2,013,467 | +306.2% | 12.38% | +171.3% |
| DHR | Buy | DANAHER CORPORATION | $32,419,197 | +7.1% | 233,957 | +18.7% | 8.06% | +50.7% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $31,023,379 | +9.9% | 275,494 | +35.8% | 7.71% | +54.7% |
| TGTX | Buy | TG THERAPEUTICS INC | $24,217,588 | +181.0% | 2,461,137 | +217.0% | 6.02% | +295.5% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $24,096,908 | +153.5% | 899,474 | +189.8% | 5.99% | +257.0% |
| CCXI | Buy | CHEMOCENTRYX INC | $23,304,842 | +14.8% | 580,011 | +13.0% | 5.79% | +61.7% |
| DCPH | Buy | DECIPHERA PHARMACEUTICALS IN | $17,047,715 | +112.7% | 414,081 | +221.6% | 4.24% | +199.5% |
| AZN | Buy | ASTRAZENECA PLCsponsored adr | $15,744,928 | +124.7% | 352,551 | +150.8% | 3.91% | +216.2% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $15,084,744 | -10.8% | 7,542,372 | +53.8% | 3.75% | +25.5% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $14,016,248 | -28.6% | 3,504,062 | +282.7% | 3.48% | +0.5% |
| HCA | New | HCA HEALTHCARE INC | $9,074,850 | – | 101,000 | +100.0% | 2.26% | – |
| MODN | Buy | MODEL N INC | $8,312,848 | +14.2% | 374,284 | +80.3% | 2.07% | +60.7% |
| DXCM | Buy | DEXCOM INC | $5,260,728 | +99.6% | 19,537 | +62.1% | 1.31% | +181.3% |
| TARO | Buy | TARO PHARMACEUTICAL INDS LTD | $4,679,291 | +974.4% | 76,459 | +1443.7% | 1.16% | +1410.4% |
| AMRN | Buy | AMARIN CORP PLCcall | $4,094,400 | -80.8% | 1,023,600 | +3.0% | 1.02% | -73.0% |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $3,986,160 | – | 146,550 | +100.0% | 0.99% | – |
| XLRN | New | ACCELERON PHARMA INC | $3,801,950 | – | 42,305 | +100.0% | 0.94% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $3,620,282 | – | 106,385 | +100.0% | 0.90% | – |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $2,695,557 | – | 90,047 | +100.0% | 0.67% | – |
| GNMK | New | GENMARK DIAGNOSTICS INC | $2,159,939 | – | 524,257 | +100.0% | 0.54% | – |
| ALGN | New | ALIGN TECHNOLOGY INCput | $1,739,500 | – | 10,000 | +100.0% | 0.43% | – |
| MYOK | Buy | MYOKARDIA INC | $1,301,014 | -16.8% | 27,752 | +29.4% | 0.32% | +17.0% |
| AUTL | New | AUTOLUS THERAPEUTICS PLCspon ads | $1,257,978 | – | 210,013 | +100.0% | 0.31% | – |
| OTIC | Buy | OTONOMY INC | $1,106,622 | -47.5% | 561,737 | +2.0% | 0.28% | -26.1% |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $1,098,048 | +166.9% | 59,774 | +220.1% | 0.27% | +274.0% |
| CYCN | New | CYCLERION THERAPEUTICS INC | $893,434 | – | 337,145 | +100.0% | 0.22% | – |
| TARA | New | ARTARA THERAPEUTICS INC | $746,994 | – | 32,478 | +100.0% | 0.19% | – |
| AMRN | New | AMARIN CORP PLCput | $600,000 | – | 150,000 | +100.0% | 0.15% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $491,638 | – | 58,251 | +100.0% | 0.12% | – |
| AL | New | AIR LEASE CORPput | $442,800 | – | 20,000 | +100.0% | 0.11% | – |
| ZGNX | New | ZOGENIX INCcall | $136,015 | – | 5,500 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-11-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMARIN CORP PLC | 21 | Q3 2023 | 12.5% |
| DANAHER CORPORATION | 21 | Q3 2023 | 8.1% |
| AFFIMED N V | 20 | Q3 2023 | 0.9% |
| ARGENX SE | 19 | Q3 2023 | 2.0% |
| GSK PLC | 18 | Q2 2022 | 13.1% |
| ASCENDIS PHARMA A/S | 18 | Q1 2022 | 7.7% |
| SANOFI | 18 | Q4 2022 | 7.2% |
| ENSIGN GROUP INC | 18 | Q1 2022 | 8.6% |
| CENTENE CORP DEL | 18 | Q3 2023 | 1.5% |
| ZOGENIX INC | 17 | Q4 2021 | 12.4% |
View Eversept Partners, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cabaletta Bio, Inc. | February 14, 2023 | 282,874 | 1.0% |
| Teligent, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| Teligent, Inc. | February 14, 2020 | 4,501,799 | 8.4% |
View Eversept Partners, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
| 13F-HR/A | 2023-11-08 |
View Eversept Partners, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.